Earnings ·
Solventum reported second-quarter 2026 financial results with net sales of $2.2 billion, a 2.2% increase on a reported…
SOLVSolventum Corp
Solventum reported second-quarter 2026 financial results with net sales of $2.2 billion, a 2.2% increase on a reported basis and a 9.5% increase organically. GAAP diluted earnings per share were $0.53, while adjusted diluted EPS rose 50.9% to $2.55. Operating cash flow reached $227 million and free cash flow was $144 million. The company announced its intent to separate its Health Information Systems business segment as part of a portfolio optimization strategy. Additionally, Solventum increased its full-year 2026 guidance for organic sales growth to +2.5% to +3.0%, adjusted EPS to $7.10–$7.20, and free cash flow to $200 million–$300 million. Solventum operates in the medical technology industry, providing advanced wound care, infection prevention, surgical solutions, dental products, and health information systems.